A groundbreaking study has discovered a possible treatment for herpes simplex virus 1 (HSV-1), the oral strain of herpes that affects over 122 million people in the US. Researchers from Spain have found that blocking an enzyme called topoisomerase I can stop HSV-1 from spreading and replicating in the body.
The team analyzed human cells infected with HSV-1 and found that the virus “hijacks” a specific enzyme to replicate itself. However, if this enzyme is blocked, it prevents the virus from taking over the cell’s DNA. This breakthrough could lead to a new therapeutic target for treating HSV-1 infections.
HSV-1 is spread through close skin-to-skin contact and causes painful blisters around the mouth and lips. While antiviral medications can manage symptoms, there is currently no cure for the virus itself. However, researchers are hopeful that this new discovery may help address the public health burden of HSV-1.
The study’s findings provide evidence that HSV-1 reshapes a person’s DNA within hours of infection, which could lead to devastating complications such as dementia if left unmanaged. Globally, nearly 4 billion people have HSV-1, and experts are concerned about the development of drug-resistant strains, which could increase transmission.
The researchers suggest that topoisomerase inhibitors, commonly used in cancer treatment, may be effective in slowing down the spread of HSV-1. These drugs can be given as pills or intravenously and cost anywhere from $8 to $61. While more evidence is needed, this study could be a crucial step towards preventing worldwide herpes outbreaks.
The discovery offers new hope for those living with HSV-1, but it’s essential to note that the virus still has no cure. However, this breakthrough may provide a new therapeutic target and management strategy for treating HSV-1 infections in the future.
Source: https://www.dailymail.co.uk/health/article-14828771/experts-herpes-virus-treatment-suffered-millions.html